Evidence map›Paper›PMID 41991688›Full record

ArticleNature medicine2026

Integrated epidemiological and molecular data inform the relationship between precancer and cancer states of esophageal adenocarcinoma.

Shahriar A Zamani, Lianlian Wu, Emily L Black, Alexander Bartram, Alvin W T Ng, Maria Secrier, Jacqueline D Perelman, Ahsen Ustaoglu, Emma Ococks, Daniel Jacobson and 11 more

Abstract read
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Shahriar A Zamani *Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK. shahriar.zamani@nih.gov.ORCID http://orcid.org/0000-0001-8622-5013
Lianlian Wu *Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Emily L BlackEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Alexander BartramEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-4652-5297
Alvin W T NgEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-4672-0815
Maria SecrierUCL Genetics Institute, Department of Genetics, Evolution and Environment, University College London, London, UK.ORCID http://orcid.org/0000-0003-2758-1741
Jacqueline D PerelmanEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Ahsen UstaogluEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-9175-7089
Emma OcocksEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Daniel JacobsonEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Ginny DevonshireEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Nicola GrehanEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Barbara NützingerEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Adam FreemanEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-8376-7498
Ahmad MiremadiDepartment of Pathology, Cambridge University Hospital NHS Trust, Cambridge, UK.
Maria O'DonovanDepartment of Pathology, Cambridge University Hospital NHS Trust, Cambridge, UK.
Alexander M FrankellEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-0341-7878
Sarah KillcoyneEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-3686-6167
Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium
Helen G ColemanCancer Epidemiology Research Group, Centre for Public Health, Queen's University Belfast, Belfast, UK.
Rebecca C FitzgeraldEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK. rcf29@cam.ac.uk.ORCID http://orcid.org/0000-0002-3434-3568

Funding

Cancer Research UK (CRUK) A15874Cancer Research UK (CRUK) A22131Cancer Research UK (CRUK) A22720RCUK | Medical Research Council (MRC) MR/W014122/1
6 · The paper itself

Abstract

Cancer generally takes years to evolve, and early diagnosis can prevent life-threatening cancer. Establishing a link between precancerous states and cancer is essential for effective screening and prevention. Esophageal adenocarcinoma (EAC) is an increasingly prevalent, poor-outcome cancer, and its presumed precursor, Barrett's esophagus (BE), characterized by intestinal metaplasia, is evident in only about half of cases. Here to test whether BE is a prerequisite to EAC, we integrated epidemiological and clinical characteristics in a prospective cohort of 3,100 patients with EAC for any evidence of BE (BE-positive and BE-negative) and compared genomic features using a subset of 710 patients with whole-genome sequencing and 87 patients (380 samples) with multiregional whole-exome sequencing. Demographic and genomic features typically associated with BE were observed across BE-positive and BE-negative EAC cases. Notably, molecular features consistent with early BE evolution were detected in both phenotypes. Advanced tumor stage was the only variable that corresponded with increased likelihood of BE-negative EAC, including in some patients with a previous BE diagnosis. Phylogenetic analyses revealed shared evolutionary trajectories, and spatial transcriptomic and proteomic analyses demonstrated intestinal metaplasia-associated lineage markers in both groups. These findings suggest a single pathway to EAC, with implications for early diagnosis and prevention strategies.

Indexed as

AdenocarcinomaBarrett EsophagusEsophageal NeoplasmsPrecancerous ConditionsAgedExome SequencingFemaleHumansMaleMiddle AgedPhylogenyProspective StudiesWhole Genome Sequencing

Identifiers

PMID41991688
PMCPMC13190344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.